losartan has been researched along with Sepsis in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 7.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP." | 5.35 | Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. ( Cai, L; Kong, T; Mo, H; Qi, J; Shen, L; Xiao, Z; Ye, J; Zheng, W, 2009) |
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 3.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP." | 1.35 | Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. ( Cai, L; Kong, T; Mo, H; Qi, J; Shen, L; Xiao, Z; Ye, J; Zheng, W, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XS | 1 |
| Wang, SH | 1 |
| Liu, CY | 1 |
| Gao, YL | 1 |
| Meng, XL | 1 |
| Wei, W | 1 |
| Shou, ST | 1 |
| Liu, YC | 1 |
| Chai, YF | 1 |
| Leisman, DE | 1 |
| Fernandes, TD | 1 |
| Bijol, V | 1 |
| Abraham, MN | 1 |
| Lehman, JR | 1 |
| Taylor, MD | 1 |
| Capone, C | 1 |
| Yaipan, O | 1 |
| Bellomo, R | 1 |
| Deutschman, CS | 1 |
| Shen, L | 1 |
| Mo, H | 1 |
| Cai, L | 1 |
| Kong, T | 1 |
| Zheng, W | 1 |
| Ye, J | 1 |
| Qi, J | 1 |
| Xiao, Z | 1 |
| Yasuda, S | 1 |
| Lew, WY | 1 |
| Tadros, T | 1 |
| Traber, DL | 1 |
| Herndon, DN | 1 |
5 other studies available for losartan and Sepsis
| Article | Year |
|---|---|
Losartan attenuates sepsis-induced cardiomyopathy by regulating macrophage polarization via TLR4-mediated NF-κB and MAPK signaling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2022 |
Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury.
Topics: Acute Kidney Injury; Angiotensin II; Animals; Case-Control Studies; Humans; Losartan; Mice; Receptor | 2021 |
Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases.
Topics: Acute Lung Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Interleukin- | 2009 |
Angiotensin II exacerbates lipopolysaccharide-induced contractile depression in rabbit cardiac myocytes.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Calcium; Cells, Cultured; Chelating Agents; Cyclic | 1999 |
Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Animals; Burns; Drug Evaluation, Preclinical; Escherichia coli | 2000 |